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Preoperative statin therapy reduces postoperative all-cause mortality
in cardiac surgery: A meta-analysis of controlled studies
Hisato Takagi, MD, PhD, Norikazu Kawai, MD, and Takuya Umemoto, MD, PhD, Shizuoka, Japan
BRIEF COMMUNICATIONS: RESEARCHTwo recent meta-analyses1,2 demonstrated that postopera-
tive mortality was significantly lower in patients undergo-
ing cardiac surgery who received preoperative statin
therapy than in those who did not. The meta-analysis by
Kapoor and associates,1 however, included merely 4 pub-
lished articles, and that by Hindler and colleagues2 cited
4 published articles and 3 scientific abstracts. Therefore,
the appropriate role of preoperative statin therapy in
cardiac surgery remains unclear. Furthermore, several con-
trolled studies of preoperative statin therapy in cardiac
surgery have been published to date since the 2 meta-anal-
yses were conducted. Herein, we performed a meta-analy-
sis of controlled studies of preoperative statin therapy for
prevention of postoperative all-cause mortality in cardiac
surgery.
MATERIALS AND METHODS
All controlled studies (English-language full-text journal publications
excluding scientific abstracts) of preoperative statin therapy in cardiac sur-
gery were identified by a 2-level search strategy. First, a public domain da-
tabase (MEDLINE) was searched using a Web-based search engine
(PubMed). Second, relevant studies were identified through a manual search
of secondary sources including references of initially identified articles and
a search of reviews and commentaries. The MEDLINE database was
searched from January 1966 to December 2007. MeSH keywords included
‘‘Hydroxymethylglutaryl-CoA Reductase Inhibitors’’ and ‘‘Cardiac Surgi-
cal Procedures.’’ Studies considered for inclusionmet the following criteria:
the design was a controlled study of preoperative statin therapy; the study
population was patients undergoing cardiac surgery; and main outcomes in-
cluded postoperative all-cause mortality. Data regarding detailed inclusion
criteria and mortality were abstracted (as available) from each individual
study. For each study, data regarding mortality in both the statin and control
(placebo or no statin) groups were used to generate crude odds ratios (ORs)
and 95% confidence intervals (CIs). We also abstracted adjusted ORs and
95% CIs for mortality if reported. Study-specific estimates were combined
using inverse variance-weighted averages of logarithmic ORs in a random-
effects model. Between-study heterogeneity was analyzed bymeans of stan-
dard c2 tests. Publication bias was assessed mathematically using an ad-
justed rank-correlation test.
RESULTS
Our search identified 13 controlled studies of preoper-
ative statin therapy in cardiac surgery, the majority of
From the Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka,
Japan.
Received for publication Jan 22, 2008; accepted for publication Feb 24, 2008.
Address for reprints: Hisato Takagi,MD, PhD, Department of Cardiovascular Surgery,
Shizuoka Medical Center, 762-1 Nagasawa, Shimizu-cho, Sunto-gun, Shizuoka
411-8611, Japan (E-mail: kfgth973@ybb.ne.jp).
J Thorac Cardiovasc Surg 2009;137:e52-3
0022-5223/$36.00
Copyright  2009 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2008.02.045e52 The Journal of Thoracic and Cardiovascular Surwhich was coronary artery bypass graft surgery (Table
1). These included 3 randomized controlled trials,3-5 3
prospective cohort studies, and 7 retrospective cohort
studies. Pooled analysis of crude ORs from all 13 studies
(representing 19,542 patients) demonstrated a statistically
significant 45% reduction in postoperative all-cause mor-
tality with preoperative statin therapy relative to control
(pooled crude OR, 0.55; 95% CI, 0.46–0.66; P < .01).
There was neither study heterogeneity of results (P ¼
.64) nor evidence of significant publication bias (P ¼
.74). Six of the 10 observational studies reported adjusted
ORs for mortality by multivariate analysis or propensity
score matching. When adjusted ORs from these 6 obser-
vational studies and ORs from the 3 randomized con-
trolled trials3-5 were pooled (representing 18,637
patients), preoperative statin therapy was associated
with a 25% reduction in mortality relative to control
that remained statistically significant (pooled adjusted
OR, 0.76; 95% CI, 0.64–0.90; P< .01). There was nei-
ther study heterogeneity of results (P ¼ .60) nor evi-
dence of significant publication bias (P ¼ .53). Pooled
analysis of ORs and adjusted Ors, respectively, from 2
randomized controlled trials3,4 and 3 observational stud-
ies that enrolled patients undergoing coronary artery by-
pass graft surgery exclusively (representing 7205
patients) demonstrated a statistically significant 41% re-
duction in mortality with preoperative statin therapy rel-
ative to control (adjusted OR, 0.59; 95% CI, 0.36–0.97;
P ¼ .04). There was neither study heterogeneity of re-
sults (P ¼ .57) nor evidence of significant publication
bias (P ¼ .62).
DISCUSSION
The present meta-analysis of 13 controlled studies dem-
onstrated that preoperative statin therapy reduced postoper-
ative all-cause mortality in cardiac surgery. The analysis,
however, included 10 observational studies but merely 3
small randomized controlled trials (sample size: 40, 77,
and 200).3-5 In an attempt to correct for and minimize se-
lection bias, which exists in observational studies, related
to statin use, we pooled adjusted instead of crude ORs
from the observational studies and ORs from the random-
ized controlled trials, resulting in a statistically significant
benefit of preoperative statin therapy for mortality in
cardiac surgery or exclusive coronary artery bypass graft
surgery. Nevertheless, larger randomized controlled trials
are needed to confirm our results. Until sufficient numbers
of events will be accumulated by evidence from random-
ized controlled trials to provide a definitive answer,gery c January 2009
Brief Communicationsadvocating routine preoperative statin therapy in cardiac
surgery is premature.
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TABLE 1. Characteristics and outcomes of included studies
OR (95% CI) for mortality
Author Publication Design Sample size Type of operation Crude Adjusted
Ali and Buth Int J Cardiol.
2005;103:12-8
Retrospective cohort 5,469 Cardiac surgery (Isolated
CABG 80%)
0.50 (0.38–0.67) 0.87 (0.61-1.25)*
Chello et al4 Crit Care Med.
2006;34:660-7
Randomized controlled 40 Elective isolated CABG 1.00 (0.02–52.85)
Christenson3 Eur J Cardiothorac Surg.
1999;15:394-400
Randomized controlled 77 Elective isolated CABG 0.93 (0.02–47.85)
Clark et al J Thorac Cardiovasc
Surg. 2006;131:
679-85
Retrospective cohort 3,829 Elective cardiac surgery
(any CABG 81%)
0.43 (0.28–0.66) 0.51 (0.27-0.94)*
Coleman et al Curr Med Res Opin.
2007;23:1783-90.
Retrospective cohort 1,934 Cardiac surgery (isolated
CABG 63%)
0.68 (0.45–1.03) 0.80 (0.64-0.99)y
Collard et al J Thorac Cardiovasc
Surg. 2006;132:
392-400
Prospective cohort 2,666 Elective primary isolated
CABG
0.79 (0.47–1.33) 0.04 (0.08-0.93)y
Dotani et al Am J Cardiol.
2000;86:1128-30, A6
Retrospective cohort 323 Elective isolated CABG 0.12 (0.01–2.08) NR
Liakopoulos et al Thorac Cardiovasc Surg.
2006;54:250-4
Prospective cohort 36 Elective isolated CABG 1.00 (0.02–53.12) NR
Mariscalco et al Ann Thorac Surg.
2007;84:1158-64
Retrospective cohort 405 Elective primary isolated
CABG
0.28 (0.01–7.03) NR
Pan et al Circulation. 2004;110(11
Suppl 1):II45-9
Retrospective cohort 1,663 Primary isolated CABG 0.47 (0.25–0.87) 0.58 (0.31–1.09)*
Pascual et al Ann Thorac Surg.
2006;81:78-83
Prospective cohort 141 Elective isolated CABG 0.16 (0.03–0.79) NR
Patti et al5 Circulation.
2006;114:1455-61
Randomized controlled 200 Elective cardiac surgery
(isolated CABG 79%)
0.98 (0.14–7.10)
Thielmann et al J Thorac Cardiovasc
Surg. 2007;134:
1143-9
Retrospective cohort 2,759 Elective primary isolated
CABG
1.08 (0.39–3.00) 1.18 (0.36–3.87)*
Total 19,542 0.55 (0.46–0.66)z 0.76 (0.64–0.90)z
OR, Odds ratio; CI, confidence interval; CABG, coronary artery bypass graft surgery; NR, not reported. *Propensity score matching. yMultivariate analysis. zPooled estimate using
a random-effects model.The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 1 e53
